MRNA
Price
$25.13
Change
+$0.85 (+3.50%)
Updated
Sep 5, 04:59 PM (EDT)
Capitalization
9.45B
54 days until earnings call
TECH
Price
$54.40
Change
+$1.48 (+2.80%)
Updated
Sep 5, 04:59 PM (EDT)
Capitalization
8.46B
60 days until earnings call
Interact to see
Advertisement

MRNA vs TECH

Header iconMRNA vs TECH Comparison
Open Charts MRNA vs TECHBanner chart's image
Moderna
Price$25.13
Change+$0.85 (+3.50%)
Volume$264.11K
Capitalization9.45B
Bio-Techne
Price$54.40
Change+$1.48 (+2.80%)
Volume$30K
Capitalization8.46B
MRNA vs TECH Comparison Chart in %
Loading...
MRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TECH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MRNA vs. TECH commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MRNA is a Hold and TECH is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (MRNA: $25.14 vs. TECH: $54.41)
Brand notoriety: MRNA: Notable vs. TECH: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MRNA: 139% vs. TECH: 80%
Market capitalization -- MRNA: $9.45B vs. TECH: $8.46B
MRNA [@Biotechnology] is valued at $9.45B. TECH’s [@Biotechnology] market capitalization is $8.46B. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MRNA’s FA Score shows that 1 FA rating(s) are green whileTECH’s FA Score has 2 green FA rating(s).

  • MRNA’s FA Score: 1 green, 4 red.
  • TECH’s FA Score: 2 green, 3 red.
According to our system of comparison, TECH is a better buy in the long-term than MRNA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MRNA’s TA Score shows that 4 TA indicator(s) are bullish while TECH’s TA Score has 4 bullish TA indicator(s).

  • MRNA’s TA Score: 4 bullish, 5 bearish.
  • TECH’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, TECH is a better buy in the short-term than MRNA.

Price Growth

MRNA (@Biotechnology) experienced а +4.36% price change this week, while TECH (@Biotechnology) price change was -0.40% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.48%, and the average quarterly price growth was +31.71%.

Reported Earning Dates

MRNA is expected to report earnings on Oct 30, 2025.

TECH is expected to report earnings on Nov 04, 2025.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MRNA($9.45B) has a higher market cap than TECH($8.46B). TECH YTD gains are higher at: -24.135 vs. MRNA (-39.538). TECH has higher annual earnings (EBITDA): 283M vs. MRNA (-2.72B). TECH has less debt than MRNA: TECH (423M) vs MRNA (741M). MRNA has higher revenues than TECH: MRNA (3.06B) vs TECH (1.21B).
MRNATECHMRNA / TECH
Capitalization9.45B8.46B112%
EBITDA-2.72B283M-962%
Gain YTD-39.538-24.135164%
P/E RatioN/A118.28-
Revenue3.06B1.21B253%
Total Cash5.13BN/A-
Total Debt741M423M175%
FUNDAMENTALS RATINGS
MRNA vs TECH: Fundamental Ratings
MRNA
TECH
OUTLOOK RATING
1..100
6052
VALUATION
overvalued / fair valued / undervalued
1..100
56
Fair valued
4
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9680
PRICE GROWTH RATING
1..100
6561
P/E GROWTH RATING
1..100
312
SEASONALITY SCORE
1..100
9050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECH's Valuation (4) in the Biotechnology industry is somewhat better than the same rating for MRNA (56). This means that TECH’s stock grew somewhat faster than MRNA’s over the last 12 months.

TECH's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as MRNA (100). This means that TECH’s stock grew similarly to MRNA’s over the last 12 months.

TECH's SMR Rating (80) in the Biotechnology industry is in the same range as MRNA (96). This means that TECH’s stock grew similarly to MRNA’s over the last 12 months.

TECH's Price Growth Rating (61) in the Biotechnology industry is in the same range as MRNA (65). This means that TECH’s stock grew similarly to MRNA’s over the last 12 months.

MRNA's P/E Growth Rating (3) in the Biotechnology industry is in the same range as TECH (12). This means that MRNA’s stock grew similarly to TECH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MRNATECH
RSI
ODDS (%)
Bullish Trend 2 days ago
76%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
71%
Momentum
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
67%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
61%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
68%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
69%
Advances
ODDS (%)
Bullish Trend 19 days ago
78%
Bullish Trend 24 days ago
72%
Declines
ODDS (%)
Bearish Trend 8 days ago
85%
Bearish Trend 2 days ago
71%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
83%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 4 days ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
MRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TECH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DAEMX15.55N/A
N/A
Dunham Emerging Markets Stock A
VIGAX238.85N/A
N/A
Vanguard Growth Index Admiral
BAUAX30.00N/A
N/A
Brown Advisory Small-Cap Fdmtl Val Adv
SPINX22.01N/A
N/A
SEI S&P 500 Index A (SIIT)
GGZPX24.32N/A
N/A
Goldman Sachs Enhanced U.S. Equity P